Unilever - Q1 FY2026 Earnings Analysis

Performance Highlights

Unilever reported Q1 2026 turnover of €12.6 billion, down 3.3% in reported terms as a 7.7% currency headwind overwhelmed underlying sales growth of 3.8%, which came in at the lower bound of the company's 4–6% multi-year target range. Volume growth of 2.9% and price growth of 0.9% were broadly in line with expectations, confirming a volume-led trajectory consistent with management's strategic framing.

The standout operating driver was Home Care, which delivered 6.1% underlying sales growth entirely on the back of 6.2% volume growth, powered by double-digit gains in India laundry liquids and a return to positive volume in Brazil following corrective pricing actions in late 2025. Power Brands — representing 78% of turnover — grew 5.0% with 4.0% volume growth, outpacing the group average, while emerging markets collectively contributed 5.7% underlying sales growth with 4.2% volume.

Management Outlook and Forward Catalysts

Management reconfirmed full-year 2026 guidance for underlying sales growth at the bottom end of the 4–6% range, at least 2% volume growth, and a modest improvement in underlying operating margin versus the 20.0% delivered in 2025, with pricing expected to play a larger role in the second half as commodity cost pressures build. The Foods-McCormick combination, structured as a Reverse Morris Trust with $15.7 billion in cash proceeds to Unilever, is expected to close by mid-2027, repositioning Unilever as a focused HPC pureplay and funding €6 billion of share buybacks through 2029.

Bulls will focus on whether volume momentum in emerging markets — particularly India at 7% and Latin America's recovery — can offset a persistently soft Europe, and whether the €800 million productivity programme, already 94% delivered by end of Q1, provides incremental margin headroom. Bears will watch FX drag, guided at approximately 3% on full-year turnover and 20 basis points on margin, alongside execution risk around the Foods separation, €400–500 million in stranded costs, and the timeline to close regulatory approvals by mid-2027.